| For: | Zhan TA, Xia F, Huang HW, Zhan JC, Liu XK, Cheng Q. Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(9): 108649 [PMID: 40977663 DOI: 10.4251/wjgo.v17.i9.108649] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v17/i9/108649.htm |
| Number | Citing Articles |
| 1 |
Arndt Vogel, Robin Kate Kelley. Systemic therapy for HCC: Doublets, triplets and beyond. Journal of Hepatology 2026; doi: 10.1016/j.jhep.2026.04.024
|
| 2 |
Jing He, Xiao-Qin Wu, Zhen-Guang Wang. Advances in the Management of Hepatocellular Carcinoma: Evolving Systemic Therapy, Perioperative Strategies, and Care for Special Populations. Journal of Clinical Question 2026; 3(2) doi: 10.69854/jcq.2026.0014
|
| 3 |
Ramaiyan Velmurugan, J. Sam Helinto, S. Subhashri, Lokeshvar Ravikumar. Artificial intelligence and nanotechnology in hepatocellular carcinoma: Implications for molecular pathology and precision diagnostics. Next Nanotechnology 2026; 9 doi: 10.1016/j.nxnano.2026.100551
|
| 4 |
Kirti C. Thombare, Sharav A. Desai, Vipul P. Patel, Madhulika J. More, Siddhi P. Sapkal, Aditi A. Kate. Molecular simulation-guided discovery and experimental validation of 7-Methoxyflavone as a selective FGFR4 inhibitor in hepatocellular carcinoma. In Silico Research in Biomedicine 2026; 2 doi: 10.1016/j.insi.2026.100288
|